Eli Lilly Reports 52-Week Results Showing Improved Efficacy From TOGETHER-Psa Phase 3b Open-Label Clinical Trial Evaluating Taltz-Zepbound Combination In Psoriatic Arthritis

Benzinga
Open on Benzinga